JP2002505100A - 種間核移植によって作製された胚性または幹細胞様細胞株 - Google Patents
種間核移植によって作製された胚性または幹細胞様細胞株Info
- Publication number
- JP2002505100A JP2002505100A JP2000534632A JP2000534632A JP2002505100A JP 2002505100 A JP2002505100 A JP 2002505100A JP 2000534632 A JP2000534632 A JP 2000534632A JP 2000534632 A JP2000534632 A JP 2000534632A JP 2002505100 A JP2002505100 A JP 2002505100A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- embryonic
- human
- nuclear transfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 97
- 210000004027 cell Anatomy 0.000 claims abstract description 447
- 238000000034 method Methods 0.000 claims abstract description 115
- 210000000287 oocyte Anatomy 0.000 claims abstract description 114
- 241000282414 Homo sapiens Species 0.000 claims abstract description 96
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 75
- 230000006907 apoptotic process Effects 0.000 claims abstract description 23
- 241000894007 species Species 0.000 claims abstract description 21
- 238000011161 development Methods 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 238000002054 transplantation Methods 0.000 claims abstract description 15
- 210000003855 cell nucleus Anatomy 0.000 claims abstract description 6
- 230000006801 homologous recombination Effects 0.000 claims abstract description 5
- 238000002744 homologous recombination Methods 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims description 57
- 210000005260 human cell Anatomy 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 30
- 241000288906 Primates Species 0.000 claims description 28
- 210000002950 fibroblast Anatomy 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 108050006400 Cyclin Proteins 0.000 claims description 19
- 230000004927 fusion Effects 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 230000004069 differentiation Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 102000016736 Cyclin Human genes 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000007159 enucleation Effects 0.000 claims description 11
- 210000002569 neuron Anatomy 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 210000001082 somatic cell Anatomy 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 9
- 210000003981 ectoderm Anatomy 0.000 claims description 9
- 210000001900 endoderm Anatomy 0.000 claims description 9
- 210000003716 mesoderm Anatomy 0.000 claims description 9
- 210000002510 keratinocyte Anatomy 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 210000004602 germ cell Anatomy 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- -1 Bcl-w Proteins 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000001612 chondrocyte Anatomy 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 210000003061 neural cell Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 claims description 3
- 101710164022 ATP-dependent RNA helicase A Proteins 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 208000026723 Urinary tract disease Diseases 0.000 claims description 3
- 208000012931 Urologic disease Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 208000014001 urinary system disease Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 claims description 2
- 101001047514 Bos taurus Lethal(2) giant larvae protein homolog 1 Proteins 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 claims description 2
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims description 2
- 101150068639 Hnf4a gene Proteins 0.000 claims description 2
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 claims description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 claims description 2
- 208000005230 Leg Ulcer Diseases 0.000 claims description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims description 2
- 101150039936 ced-9 gene Proteins 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 229940123169 Caspase inhibitor Drugs 0.000 claims 1
- 101000743587 Homo sapiens Vacuolar protein sorting-associated protein 26A Proteins 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- 102100038398 Vacuolar protein sorting-associated protein 26A Human genes 0.000 claims 1
- 102000055104 bcl-X Human genes 0.000 claims 1
- 108700000711 bcl-X Proteins 0.000 claims 1
- 208000015100 cartilage disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 19
- 230000018109 developmental process Effects 0.000 abstract description 18
- 230000022131 cell cycle Effects 0.000 abstract description 10
- 230000012010 growth Effects 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000024245 cell differentiation Effects 0.000 abstract description 4
- 210000004940 nucleus Anatomy 0.000 description 40
- 210000002257 embryonic structure Anatomy 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 27
- 210000002459 blastocyst Anatomy 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000001161 mammalian embryo Anatomy 0.000 description 21
- 239000002609 medium Substances 0.000 description 18
- 210000002308 embryonic cell Anatomy 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 230000013020 embryo development Effects 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 230000009261 transgenic effect Effects 0.000 description 13
- 210000004102 animal cell Anatomy 0.000 description 12
- 239000012894 fetal calf serum Substances 0.000 description 12
- 230000035800 maturation Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 10
- 230000002950 deficient Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000002955 isolation Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000031864 metaphase Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000283726 Bison Species 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000002718 aborted fetus Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 108700042656 bcl-1 Genes Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000029803 blastocyst development Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- LPIARALSGDVZEP-SJVNDZIOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 LPIARALSGDVZEP-SJVNDZIOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 101100216424 African swine fever virus (strain E-70 MS44) LMW5-HL gene Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 229940123063 Caspase 4 inhibitor Drugs 0.000 description 1
- 229940122396 Caspase 9 inhibitor Drugs 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000120595 Haloragis Species 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 description 1
- 101000572981 Homo sapiens POU domain, class 3, transcription factor 1 Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100020949 Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102100021543 Solute carrier family 22 member 16 Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940123098 caspase 6 inhibitor Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 230000008913 ectoderm development Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 230000020619 endoderm development Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001158 estrous effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003847 mesoderm development Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150006864 ped gene Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150117196 tra-1 gene Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3294598A | 1998-03-02 | 1998-03-02 | |
| US09/032,945 | 1998-03-02 | ||
| PCT/US1999/004608 WO1999045100A1 (en) | 1998-03-02 | 1999-03-02 | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002505100A true JP2002505100A (ja) | 2002-02-19 |
| JP2002505100A5 JP2002505100A5 (enExample) | 2006-06-15 |
Family
ID=21867727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000534632A Pending JP2002505100A (ja) | 1998-03-02 | 1999-03-02 | 種間核移植によって作製された胚性または幹細胞様細胞株 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1060243A4 (enExample) |
| JP (1) | JP2002505100A (enExample) |
| CN (1) | CN1299408A (enExample) |
| AU (1) | AU759322B2 (enExample) |
| BR (1) | BR9908499A (enExample) |
| CA (1) | CA2323094A1 (enExample) |
| IL (1) | IL138201A0 (enExample) |
| NZ (1) | NZ506808A (enExample) |
| WO (1) | WO1999045100A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148547A0 (en) * | 1999-09-14 | 2002-09-12 | Univ Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| BR0014864A (pt) * | 1999-10-15 | 2002-11-19 | Advanced Cell Tech Inc | Métodos de produzir células progenitoras diferenciadas e células tronco embriÈnicas defeituosas em linhagem |
| CN1425064A (zh) * | 1999-12-20 | 2003-06-18 | 马萨诸塞大学 | 通过交叉物种核移植制备的胚胎或干样细胞 |
| US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| US6921665B2 (en) | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
| AU2002250020A1 (en) * | 2001-02-02 | 2002-08-19 | Erik Forsberg | Method of cloning transgenic mammalian animals using pseudonuclei |
| HUP0501094A2 (en) * | 2001-11-06 | 2006-04-28 | Univ Shanghai 2Nd Medical | Somatic cell derived embryonic stem cells and its differentiated cells |
| HUP0401692A3 (en) * | 2001-11-06 | 2005-02-28 | Sheng Huizhen | Preparing somatic embryo by utilizing rabbit oocyte |
| AU2003230725A1 (en) * | 2002-04-01 | 2003-10-20 | Gtc Biotherapeutics, Inc. | A method for selecting cell lines to be used for nuclear transfer in mammalian species |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| WO2013177228A1 (en) * | 2012-05-22 | 2013-11-28 | Loma Linda University | Generation of integration/transgene-free stem cells |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905042A (en) * | 1996-04-01 | 1999-05-18 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Cultured inner cell mass cell lines derived from bovine or porcine embryos |
| CN1230989A (zh) * | 1996-08-19 | 1999-10-06 | 马萨诸塞大学 | 通过种间核移植制备胚胎细胞或干细胞样细胞系 |
| NZ337495A (en) * | 1997-03-06 | 2001-06-29 | Infigen Inc | Bovine primordial germ cells and their use in cloning |
| WO1999005266A2 (en) * | 1997-07-26 | 1999-02-04 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
-
1999
- 1999-03-02 WO PCT/US1999/004608 patent/WO1999045100A1/en not_active Ceased
- 1999-03-02 IL IL13820199A patent/IL138201A0/xx not_active IP Right Cessation
- 1999-03-02 EP EP99911062A patent/EP1060243A4/en not_active Withdrawn
- 1999-03-02 BR BR9908499-6A patent/BR9908499A/pt not_active Application Discontinuation
- 1999-03-02 AU AU29795/99A patent/AU759322B2/en not_active Ceased
- 1999-03-02 JP JP2000534632A patent/JP2002505100A/ja active Pending
- 1999-03-02 CN CN99805691A patent/CN1299408A/zh active Pending
- 1999-03-02 NZ NZ506808A patent/NZ506808A/en unknown
- 1999-03-02 CA CA002323094A patent/CA2323094A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2323094A1 (en) | 1999-09-10 |
| NZ506808A (en) | 2003-12-19 |
| CN1299408A (zh) | 2001-06-13 |
| IL138201A0 (en) | 2001-10-31 |
| EP1060243A4 (en) | 2005-03-09 |
| AU759322B2 (en) | 2003-04-10 |
| AU2979599A (en) | 1999-09-20 |
| BR9908499A (pt) | 2001-12-26 |
| WO1999045100A1 (en) | 1999-09-10 |
| EP1060243A1 (en) | 2000-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1248288B (zh) | 用分化胎儿和成年供体细胞进行的核转移 | |
| US20050250203A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
| JP2002505100A (ja) | 種間核移植によって作製された胚性または幹細胞様細胞株 | |
| US20010012513A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
| JP2002537803A (ja) | 異種間核移植により産生される胚性細胞株あるいは幹様細胞株 | |
| JP2001509361A (ja) | 分化した無血清飢餓細胞からの供与核を用いるクローニング | |
| US7696404B2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
| AU784731B2 (en) | Embryonic or stem-like cells produced by cross species nuclear transplantation | |
| JP2003514515A (ja) | 核移行のためのドナー細胞の調製と選択 | |
| US20040040050A1 (en) | Production of agricultural animals from embryonic stem (es) cells | |
| JP2003509031A (ja) | ドナー細胞又は分化細胞からの核を使用する豚のクローニング並びに多能性豚の産生 | |
| AU2008229989A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
| JP2003525031A (ja) | 交雑種核移植によって産生された胚細胞または幹様細胞系及びドナー細胞の遺伝子改変または組織培養条件によって胚発達を増強する方法 | |
| MXPA00008602A (en) | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation | |
| AU2006201208A1 (en) | Embryonic or stem-like cells produced by cross species nuclear transpantation | |
| AU2005225103A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090224 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090303 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090721 |